Fudan University Shanghai Cancer Center
Fudan University Shanghai Cancer Center is China's leading breast cancer centre and the site of first-in-human TROP2 PET imaging.
Shao Zhimin's TNBC molecular subtyping and FUTURE umbrella trial, 68Ga-TROP2 nanobody PET (Song), highest breast cancer surgical volume in the world.
- TNBC subtyping (FUTURE trial)
- TROP2 PET
- Breast surgery
Dingwei Ye is China's leading uro-oncologist, whose department runs the Chinese arms of major prostate and bladder cancer trials.
Principal investigator of FRESCO, the Chinese trial that first proved fruquintinib works in refractory colorectal cancer.
Leads the nuclear medicine group behind the first human TROP2 PET imaging, aiming to pick patients for TROP2 ADCs with a scan.
A breast medical oncologist who has led Chinese trials of chemotherapy, CDK4/6 inhibitors, and ADCs in advanced breast cancer.
Co-architect of the Fudan TNBC subtypes and the metabolic and immune atlases that guide subtype-specific treatment.
Leads the world's highest-volume breast cancer surgical unit and the FUTURE trial that treats triple-negative breast cancer by molecular subtype.